Synapse - Works

Results (115370)

Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Meeting Abstract

Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Effect of prior bevacizumab treatment in BRAF V600Emutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

Meeting Abstract

Aderka, D.; Kopetz, S.; Grothey, A.; Van Cutsem, E.; Yaeger, R.; Wasan, H.; Yoshino, T.; Desai, J.; Ciardiello, F.; Golden, A.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-DOTATATE vs. high-dose octreotide in patients with progressive midgut NETs

Meeting Abstract

Strosberg, J.; Caplin, M.; Kunz, P.; Ruszniewski, P.; Bodei, L.; Hendifar, A.; Mittra, E.; Wolin, E.; Yao, J.; Pavel, M.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase fusion-positive gastrointestinal cancer: An expanded dataset

Meeting Abstract

Boni, V.; Drilon, A.; Deeken, J.; Garralda, E.; Chung, H.; Kinoshita, I.; Oh, D.; Patel, J.; Xu, R.; Norenberg, R.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma

Meeting Abstract

Ducreux, M.; Abou-Alfa, G.; Ren, Z.; Edeline, J.; Li, Z.; Assenat, E.; Rimassa, L.; Blanc, J.; Ross, P.; Fang, W.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

MOUNTAINEER: Open-label, phase 2 study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress)

Meeting Abstract

Siena, S.; Elez, E.; Peeters, M.; André, T.; Van den Eynde, M.; Ng, K.; Cercek, A.; Fountzilas, C.; Sanchez, F.; Hubbard, J.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Meeting Abstract

Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Meeting Abstract

Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Progression-free survival in patients with cholangiocarcinoma with FGFR2 fusions or rearrangements: A FIGHT-202 post-hoc analysis of prior systemic therapy response

Meeting Abstract

Abou-Alfa, G.; Sahai, V.; Hollebecque, A.; Vaccaro, G.; Melisi, D.; Al-Rajabi, R.; Paulson, A.; Borad, M.; Gallinson, D.; Murphy, A.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Meeting Abstract

Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S.; Hyung, W.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save